drugset / Trial / NCT00398567
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of HKI-272 (neratinib) in combination with trastuzumab in patients with advanced breast cancer.
Timeline
- Start
- 2007-04-04
- Primary completion
- 2009-07-31
- Completion
- 2018-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 160 mg | Oral |
| Subject | Neratinib | Small molecule | 240 mg | Oral |
| Background | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |